Croal M

Compass Pathfinder Ltd. (A Subsidiary of Compass Pathways PLC), London, UK.

7 papers · ORCID

ArticlePsilocybin

Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.

Dougherty RF, Modlin NL, McGowan NM +11

Europe PMC2026
ArticlePsilocybin

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Europe PMC2026
ArticlePsilocybin

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2026
ArticlePsilocybin

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2025
ArticlePsilocybin

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.

Marwood L, Croal M, Mistry S +4

Europe PMC2024
ArticlePsilocybin

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM, Croal M, Feifel D +11

Europe PMC2023
ArticlePsilocybin

Unblinding and demand characteristics in the treatment of depression.

Goodwin GM, Croal M, Marwood L +1

Europe PMC2023